NDAORALTABLET
Approved
Sep 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AQUATENSEN (methyclothiazide) is an oral thiazide diuretic approved in 1977 for the treatment of hypertension and edema. It works by inhibiting sodium and chloride reabsorption in the distal convoluted tubule, reducing blood volume and peripheral resistance. This legacy product represents a foundational class in antihypertensive therapy.
LOE Approaching
A mature product approaching loss of exclusivity with moderate competitive pressure (30/100); expect defensive positioning and consolidation of brand resources.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on AQUATENSEN represents a career opportunity in mature-product management and defensive commercial strategy within Bausch Health's portfolio. Limited growth potential suggests this role suits professionals focused on profitability optimization, generic containment, and portfolio rationalization rather than innovation or market expansion.
Brand ManagerField Sales Representative
Worked on AQUATENSEN at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.